Please assess the completion status of the following clinical trial:

Trial Title: Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with either breast or gynecological cancer~* Receiving either AC-like or CT MEC~* Experienced at least 1 episode of vomiting or retching during the first 5 days following Cycle 1 of chemotherapy that was thought to be due to chemotherapy. Received standard chemotherapy-induced nausea and vomiting (CINV) prophylaxis not containing aprepitant or fosaprepitant~* No change in chemotherapy at Cycle 2~* No change in Cycle 1 antiemetic regimen at Cycle 2~* Eastern Cooperative Oncology Group (ECOG) status 0-1~Exclusion Criteria:~* Requires increase in systemic corticosteroid therapy~* Used benzodiazepines or opiates in the 48 hours prior to Cycle 2 chemotherapy~* Received or will receive radiation therapy to the abdomen or pelvis in the week prior to Visit 1 or in Days 1-6 following chemotherapy~* Vomited in the 24 hours prior to Treatment Day 1~* Pregnant or breast-feeding~* Participating in a study with aprepitant or fosaprepitant or has taken an investigational drug in the last 4 weeks~* Symptomatic central nervous system metastasis~* History of other malignancies in the last 2 years

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fosaprepitant 150 mg (Type: EXPERIMENTAL): Women with breast cancer receiving anthracycline-cyclophosphamide (AC)-like chemotherapy and women with gynecological cancer receiving carboplatin-paclitaxel (CT) chemotherapy receive fosaprepitant 150 mg administered intravenously (IV) on Day 1 of Cycle 2 of chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).